SAN DIEGO, March 20 /PRNewswire/ -- Valor Medical, an emerging medical device company in San Diego, CA, announced today that the first human implant of Neucrylate AN for treatment of cerebral aneurysms was performed by Dr. Sean Pakbaz at the University of Tehran. The treatment was under the guidance of a clinical protocol that had been approved by the University's Internal Ethics Committee.
Dr. Pakbaz stated that the patient's aneurysm was a type and location that is very difficult to treat. However, the insertion of the Neucrylate AN was very smooth and the total procedure time was significantly less than if the procedure had been done with a stent and coils. "The procedure went very well. The many practice implants I performed at Valor's simulated anatomical training lab prepared me for this trial. Valor's technology will make a major impact on how cerebral aneurysms are treated."
Valor Medical's Neucrylate AN is injected into the cerebral aneurysm through a micro-infusion catheter that is first inserted in the femoral artery. Neucrylate AN is a liquid that, when it comes in contact with blood, changes into a solid spongy material. The liquid enables the surgeon to totally fill the aneurysm regardless of shape, a property that is not found with implantable coils.
A cerebral aneurysm is a swelling of an artery in the brain. As the swelling increases the blood-vessel wall weakens and can rupture, causing bleeding and death. It is estimated that over 30,000 patients in the U.S. are diagnosed with cerebral aneurysms each year, and approximately 5 million individuals are walking around in the U.S. with undiagnosed cerebral aneurysms.
CONTACT: Clark Adams, Chief Executive Officer of Valor Medical,
Web site: http://www.valormedical.com/